X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (2476) 2476
rats (1965) 1965
oxidopamine - toxicity (1691) 1691
neurosciences (1596) 1596
male (1513) 1513
index medicus (1193) 1193
parkinson's disease (1187) 1187
6-hydroxydopamine (893) 893
rats, sprague-dawley (862) 862
parkinsons-disease (839) 839
disease models, animal (764) 764
dopamine (680) 680
dopamine - metabolism (665) 665
oxidopamine (578) 578
neurons (546) 546
neurons - drug effects (517) 517
humans (494) 494
mice (477) 477
tyrosine 3-monooxygenase - metabolism (471) 471
rats, wistar (463) 463
corpus striatum - drug effects (443) 443
substantia-nigra (418) 418
female (416) 416
oxidative stress (410) 410
substantia nigra - drug effects (394) 394
adrenergic agents - toxicity (380) 380
neurology (378) 378
motor activity - drug effects (358) 358
dose-response relationship, drug (357) 357
corpus striatum - metabolism (345) 345
brain (334) 334
time factors (328) 328
neurons - metabolism (324) 324
neuroprotective agents - pharmacology (323) 323
biochemistry & molecular biology (320) 320
pharmacology & pharmacy (313) 313
neuroprotection (301) 301
oxidopamine - pharmacology (293) 293
apoptosis (290) 290
6-ohda (288) 288
basal ganglia (284) 284
analysis (269) 269
substantia nigra - metabolism (263) 263
parkinson disease - etiology (255) 255
striatum (254) 254
cell survival - drug effects (248) 248
sympatholytics - toxicity (237) 237
pc12 cells (225) 225
rat (224) 224
immunohistochemistry (222) 222
analysis of variance (221) 221
parkinson disease - pathology (221) 221
behavior, animal - drug effects (219) 219
parkinson’s disease (217) 217
parkinsonian disorders - chemically induced (216) 216
substantia nigra - pathology (211) 211
substantia nigra (210) 210
parkinson disease - drug therapy (201) 201
parkinson disease - metabolism (200) 200
neurotoxicity (199) 199
dopaminergic-neurons (197) 197
cells, cultured (193) 193
mice, inbred c57bl (184) 184
apoptosis - drug effects (182) 182
neurons - physiology (182) 182
corpus striatum - pathology (180) 180
parkinsonian disorders - metabolism (176) 176
dopamine - physiology (174) 174
nervous system (174) 174
parkinson disease, secondary - chemically induced (174) 174
cell line, tumor (170) 170
rats, inbred strains (168) 168
neurons - pathology (166) 166
parkinsonian disorders - drug therapy (166) 166
phenols (166) 166
neurodegeneration (165) 165
parkinsonian disorders - physiopathology (164) 164
dopaminergic neurons - drug effects (162) 162
apomorphine - pharmacology (161) 161
in-vivo (161) 161
brain - drug effects (159) 159
brain - metabolism (158) 158
neurodegenerative diseases (156) 156
neurotrophic factor (154) 154
movement disorders (153) 153
parkinsonian disorders - pathology (152) 152
cell biology (151) 151
model (151) 151
parkinson disease - physiopathology (148) 148
parkinsons disease (145) 145
expression (144) 144
neurotoxins - toxicity (144) 144
reactive oxygen species - metabolism (143) 143
activation (141) 141
oxidative stress - drug effects (140) 140
article (138) 138
l-dopa (132) 132
clinical neurology (130) 130
biomedicine (129) 129
cell death - drug effects (128) 128
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2606) 2606
Russian (14) 14
Chinese (7) 7
Spanish (3) 3
French (2) 2
Japanese (2) 2
German (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Toxicological Sciences, ISSN 1096-6080, 11/2013, Volume 136, Issue 1, pp. 166 - 182
Journal Article
Journal Article
Advances in Experimental Medicine and Biology, ISSN 0065-2598, 2015, Volume 837, pp. 23 - 33
Journal Article
Journal of Molecular Neuroscience, ISSN 0895-8696, 1/2013, Volume 49, Issue 1, pp. 105 - 115
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2014, Volume 9, Issue 6, pp. e100286 - e100286
Background: Mounting evidence shows that urate may become a biomarker of Parkinson's disease (PD) diagnosis and prognosis and a neuroprotectant candidate for... 
CELLS | TRANSCRIPTION FACTOR NRF2 | PROTECTION | PATHWAY | MULTIDISCIPLINARY SCIENCES | KEAP1 | DEGRADATION | SUBSTANTIA-NIGRA | URIC-ACID | PARKINSONS-DISEASE | LIGASE | Hydrogen Peroxide - toxicity | Cell Line | Signal Transduction | Humans | Protein Transport - drug effects | Gene Knockdown Techniques | Gene Expression Regulation - drug effects | Proteolysis - drug effects | Oxidopamine - toxicity | Neuroprotective Agents - pharmacology | Ubiquitination - drug effects | RNA Interference | Models, Biological | Uric Acid - pharmacology | Dopaminergic Neurons - metabolism | NF-E2-Related Factor 2 - metabolism | Cell Line, Tumor | Dopaminergic Neurons - drug effects | NF-E2-Related Factor 2 - genetics | Transcription, Genetic | Active Transport, Cell Nucleus | Neuroprotection | Cell culture | Neurosciences | Transcription factors | Hydrogen peroxide | Parkinson's disease | Transcription | Laboratories | Toxicity | Parkinsons disease | Kinases | Neuroprotective agents | Degradation | Proteins | Antioxidants | Neurotoxicity | Ubiquitination | Rodents | Heme | Pretreatment | Catalysis | Damage accumulation | Movement disorders | Glutathione | Dopamine receptors | Glutamate-cysteine ligase | Translocation | Enzymes | Immunoglobulins | Dopamine | Neurodegenerative diseases | Neurons | 6-Hydroxydopamine | Heme oxygenase (decyclizing) | siRNA | Uric acid | Gene expression | Nuclear transport | Augmentation | Studies | Oxygenase | Neurology | Signaling | Molecular modelling | Biomarkers | Index Medicus
Journal Article
Journal Article
Journal Article
Neuropharmacology, ISSN 0028-3908, 09/2017, Volume 123, pp. 88 - 99
Here, we report the characterization of a novel hybrid D /D agonist and iron (II) specific chelator, as a multi-target-directed ligand against Parkinson's... 
Neuroprotection | Parkinson's disease | Multifunctional dopamine agonist | Drosophila | 6-OHDA | MPTP | α-synuclein | HYPOXIA-INDUCIBLE FACTOR | DROSOPHILA MODEL | INTRACELLULAR IRON | SYNUCLEIN | alpha-synuclein | SUBSTANTIA-NIGRA | NEUROSCIENCES | 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE | PHARMACOLOGY & PHARMACY | KYNURENIC ACID | PC12 CELLS | PROLYL 4-HYDROXYLASE | PARKINSONS-DISEASE | Dopaminergic Neurons - pathology | Prolyl Hydroxylases - metabolism | Prolyl-Hydroxylase Inhibitors - pharmacology | 2,2'-Dipyridyl - analogs & derivatives | Male | Membrane Potential, Mitochondrial - drug effects | Corpus Striatum - metabolism | PC12 Cells | Pars Compacta - pathology | Dose-Response Relationship, Drug | Neuroprotective Agents - pharmacology | Dopaminergic Neurons - metabolism | Dopaminergic Neurons - drug effects | MPTP Poisoning - pathology | Membrane Potential, Mitochondrial - physiology | alpha-Synuclein - genetics | Corpus Striatum - pathology | Cell Survival - physiology | Dopamine - metabolism | 2,2'-Dipyridyl - pharmacology | Cell Survival - drug effects | alpha-Synuclein - toxicity | Mice, Inbred C57BL | Rats | Mitochondria - metabolism | Pars Compacta - metabolism | Mitochondria - drug effects | MPTP Poisoning - drug therapy | Piperazines - pharmacology | Pars Compacta - drug effects | Oxidopamine - toxicity | Animals | MPTP Poisoning - metabolism | Corpus Striatum - drug effects | Drosophila melanogaster | alpha-Synuclein - metabolism | Index Medicus | neuroprotection
Journal Article